FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

PEHL MICHAEL F.

2. Date of Event Requiring Statement (MM/DD/YYYY)
6/15/2016 

3. Issuer Name and Ticker or Trading Symbol

CELGENE CORP /DE/ [CELG]

(Last)        (First)        (Middle)

C/O CELGENE CORPORATION, 86 MORRIS AVENUE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
See remarks /

(Street)

SUMMIT, NJ 07901       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   1628   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)     (1) (2) 1/30/2022   Common Stock   938   $36.36   D    
Stock Option (right to buy)     (1) (2) 4/30/2022   Common Stock   1668   $36.47   D    
Stock Option (right to buy)     (2) (3) 7/30/2022   Common Stock   1668   $34.70   D    
Stock Option (right to buy)     (2) (4) 10/31/2022   Common Stock   1668   $36.68   D    
Stock Option (right to buy)     (2) (5) 12/17/2022   Common Stock   2500   $40.22   D    
Stock Option (right to buy)     (2) (6) 1/28/2023   Common Stock   3336   $49.48   D    
Stock Option (right to buy)     (2) (7) 4/29/2023   Common Stock   3752   $59.23   D    
Stock Option (right to buy)     (2) (8) 7/29/2023   Common Stock   3752   $71.33   D    
Stock Option (right to buy)     (2) (9) 10/28/2023   Common Stock   3752   $78.11   D    
Stock Option (right to buy)     (2) (10) 12/2/2023   Common Stock   3752   $81.56   D    
Stock Option (right to buy)     (2) (11) 2/3/2024   Common Stock   5626   $74.30   D    
Stock Option (right to buy)     (2) (12) 7/28/2024   Common Stock   3750   $87.64   D    
Stock Option (right to buy)     (2) (13) 10/27/2024   Common Stock   1875   $103.10   D    
Stock Option (right to buy)     (2) (14) 12/19/2024   Common Stock   5000   $117.18   D    
Stock Option (right to buy)     (2) (15) 2/2/2025   Common Stock   2500   $118.57   D    
Stock Option (right to buy)     (2) (16) 5/4/2025   Common Stock   3125   $109.90   D    
Stock Option (right to buy)     (2) (17) 7/27/2025   Common Stock   3125   $132.56   D    
Stock Option (right to buy)     (2) (18) 11/9/2025   Common Stock   3125   $114.08   D    
Stock Option (right to buy)     (2) (19) 2/1/2026   Common Stock   3125   $100.80   D    
Stock Option (right to buy)     (2) (20) 5/2/2026   Common Stock   5000   $104.97   D    
Restricted Stock Unit     (21)   (21) Common Stock   1880     (22) (23) D    
Restricted Stock Unit     (24)   (24) Common Stock   2500     (22) (23) D    
Restricted Stock Unit     (25)   (25) Common Stock   1250     (22) (23) D    
Restricted Stock Unit     (26)   (26) Common Stock   3125     (22) (23) D    
Restricted Stock Unit     (27)   (27) Common Stock   2700     (22) (23) D    
Restricted Stock Unit     (28)   (28) Common Stock   2500     (22) (23) D    

Explanation of Responses:
( 1)  The option is immediately exercisable and is fully vested.
( 2)  The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015).
( 3)  The option is immediately exercisable and will vest on July 30, 2016.
( 4)  The option is immediately exercisable and will vest on October 31, 2016.
( 5)  The option is immediately exercisable and will vest on December 17, 2016.
( 6)  The option is immediately exercisable and will fully vest on January 28, 2017.
( 7)  The option is immediately exercisable and will fully vest on April 29, 2017.
( 8)  The option is immediately exercisable and will vest in two annual installments as follows: 1,876 shares on July 29, 2016; 1,876 shares on July 29, 2017.
( 9)  The option is immediately exercisable and will vest in two annual installments as follows: 1,876 shares on October 28, 2016; 1,876 shares on October 28, 2017.
( 10)  The option is immediately exercisable and will vest in two annual installments as follows: 1,876 shares on December 2, 2016; 1,876 shares on December 2, 2017.
( 11)  The option is immediately exercisable and will vest in two annual installments as follows: 1,876 shares on February 3, 2017; 1,876 shares on February 3, 2018.
( 12)  The option is immediately exercisable and will vest in three annual installments as follows: 1,250 shares on July 28, 2016; 1,250 shares on July 28, 2017; 1,250 shares on July 28, 2018.
( 13)  The option is immediately exercisable and will vest in three annual installments as follows: 625 shares on October 27, 2016; 625 shares on October 27, 2017; 625 shares on October 27, 2017.
( 14)  The option is immediately exercisable and will vest in four equal annual installments commencing on December 19, 2015.
( 15)  The option is immediately exercisable and will vest in four equal annual installments commencing on February 2, 2016.
( 16)  The option is immediately exercisable and will vest in four equal annual installments commencing on May 4, 2016.
( 17)  The option is immediately exercisable and will vest in four equal annual installments commencing on July 27, 2016.
( 18)  The option is immediately exercisable and will vest in four equal annual installments commencing on November 9, 2016.
( 19)  The option is immediately exercisable and will vest in four equal annual installments commencing on February 1, 2017.
( 20)  The option is immediately exercisable and will vest in four equal annual installments commencing on May 2, 2017.
( 21)  The restricted stock units will vest on December 2, 2016. Vested shares will be delivered to the reporting person promptly after the vesting date.
( 22)  The restricted stock unit was issued pursuant to the Company's 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015).
( 23)  Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
( 24)  The restricted stock units will vest on July 28, 2017. Vested shares will be delivered to the reporting person on the vesting date.
( 25)  The restricted stock units will vest on December 19, 2017. Vested shares will be delivered to the reporting person on the vesting date.
( 26)  The restricted stock units will vest on May 4, 2018. Vested shares will be delivered to the reporting person on the vesting date.
( 27)  The restricted stock units will vest on December 16, 2018. Vested shares will be delivered to the reporting person on the vesting date.
( 28)  The restricted stock units will vest on May 2, 2019. Vested shares will be delivered to the reporting person on the vesting date.

Remarks:
President Hematology & Oncology

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
PEHL MICHAEL F.
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT, NJ 07901

See remarks

Signatures
/s/ Michael F. Pehl __________________________________________ Michael F. Pehl 6/24/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Celgene Charts.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Celgene Charts.